These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18790967)

  • 1. Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?
    Baselga J
    Ann Oncol; 2008 Sep; 19 Suppl 7():vii281-8. PubMed ID: 18790967
    [No Abstract]   [Full Text] [Related]  

  • 2. Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways.
    Hatake K; Tokudome N; Ito Y
    Breast Cancer; 2007; 14(2):132-49. PubMed ID: 17485898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating molecular tools into early-stage clinical trials.
    Weil RJ
    PLoS Med; 2008 Jan; 5(1):e21. PubMed ID: 18215108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American Association for Cancer Research--99th Annual Meeting. Clinical and preclinical data on promising therapeutics.
    Karger GA; Lee W
    IDrugs; 2008 Jun; 11(6):415-7. PubMed ID: 18509781
    [No Abstract]   [Full Text] [Related]  

  • 5. Emerging therapies for colorectal cancer.
    Hezel AF; Ryan DP
    Expert Opin Investig Drugs; 2007 Jun; 16(6):867-76. PubMed ID: 17501698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
    Wacheck V
    Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
    [No Abstract]   [Full Text] [Related]  

  • 7. ErbB/HER receptor family in breast cancer--the more we search the more we learn.
    Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
    Ann Oncol; 2008 May; 19(5):1020-1. PubMed ID: 18356136
    [No Abstract]   [Full Text] [Related]  

  • 8. Involvement of PI3K/Akt pathway in prostate cancer--potential strategies for developing targeted therapies.
    Pommery N; Hénichart JP
    Mini Rev Med Chem; 2005 Dec; 5(12):1125-32. PubMed ID: 16375758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours.
    Elez E; Macarulla T; Tabernero J
    Ann Oncol; 2008 Sep; 19 Suppl 7():vii146-52. PubMed ID: 18790937
    [No Abstract]   [Full Text] [Related]  

  • 10. New approaches and targets in advanced colorectal cancer.
    Macarulla T; Capdevila J; Perez-Garcia J; Ramos FJ; Elez ME; Markman B; Ruiz-Echarri M; Tabernero J
    Eur J Cancer; 2009 Sep; 45 Suppl 1():79-88. PubMed ID: 19775607
    [No Abstract]   [Full Text] [Related]  

  • 11. Heat-Shock Protein 90-Targeted Nano Anticancer Therapy.
    Rochani AK; Ravindran Girija A; Borah A; Maekawa T; Sakthi Kumar D
    J Pharm Sci; 2016 Apr; 105(4):1454-66. PubMed ID: 26886301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SRC inhibitors as potential therapeutic agents for human cancers.
    Trevino JG; Summy JM; Gallick GE
    Mini Rev Med Chem; 2006 Jun; 6(6):681-7. PubMed ID: 16787379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of targeted interference with Src-mediated signal transduction events.
    Ly QP; Yeatman TJ
    Recent Results Cancer Res; 2007; 172():169-88. PubMed ID: 17607941
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting the human kinome for cancer therapy.
    Daly RJ
    Crit Rev Oncog; 2012; 17(1):vi-vii. PubMed ID: 22471667
    [No Abstract]   [Full Text] [Related]  

  • 15. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
    Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L
    Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From the bench to the bed side: PI3K pathway inhibitors in clinical development.
    Maira SM; Finan P; Garcia-Echeverria C
    Curr Top Microbiol Immunol; 2010; 347():209-39. PubMed ID: 20582534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the PI3K pathway: hope we can believe in?
    van der Heijden MS; Bernards R
    Clin Cancer Res; 2010 Jun; 16(12):3094-9. PubMed ID: 20400520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives in central nervous system malignancies.
    Stummer W
    IDrugs; 2006 Jun; 9(6):412-4. PubMed ID: 16752310
    [No Abstract]   [Full Text] [Related]  

  • 19. Src kinases as targets for B cell acute lymphoblastic leukaemia therapy.
    Li S
    Expert Opin Ther Targets; 2005 Apr; 9(2):329-41. PubMed ID: 15934919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor.
    Li T; Chen X; Dai XY; Wei B; Weng QJ; Chen X; Ouyang DF; Yan R; Huang ZJ; Jiang HL; Zhu H; Lu JJ
    Toxicol Appl Pharmacol; 2017 Sep; 330():65-73. PubMed ID: 28711525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.